Status:
RECRUITING
OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study
Lead Sponsor:
Gynaecologisch Oncologisch Centrum Zuid
Collaborating Sponsors:
Eindhoven University of Technology
Radboud University Medical Center
Conditions:
Ovarian Neoplasms
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Ovarian cancer (OC) is one of the most lethal cancers in the world due to late-stage disease at diagnosis. Standard therapy consists of debulking surgery and chemotherapy. However, despite this aggres...
Detailed Description
INTRODUCTION AND RATIONALE Problem description/ unmet needs: Ovarian cancer is the fifth leading cause of cancer death among women in the Western world. The high mortality rate is due to detection a...
Eligibility Criteria
Inclusion
- Subjects should be at least 18 years old and mentally competent;
- Newly diagnosed patients with OC who go for primary debulking surgery or patients with OC who are scheduled for interval debulking;
- Controls: women who undergo surgery for benign gynaecological conditions under general anaesthesia.
Exclusion
- Mentally incompetent;
- Pregnant or breastfeeding;
- Known inflammatory of infectious diseases or an immunosuppressive status;
- Using medication interfering with the immune system;
- Severe comorbidities: other active malignancy (except for basal cell carcinoma and other in situ carcinomas);
- Serious psychiatric pathology;
- A self reported alcohol consumption of \>21 units per week.
Key Trial Info
Start Date :
January 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06611072
Start Date
January 1 2025
End Date
December 1 2027
Last Update
December 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Catharina Hospital
Eindhoven, North Brabant, Netherlands, 5623EJ